Reporting progress of R&D aimed at expanding BNCT indications into deep-seated cancer areas in collaboration with Fujita Medical University and others. Conducted exploratory research using 18F-FBPA PET, laying the groundwork for expanding indications to deep-seated tumors. Positioned as a pillar of the long-term growth strategy including transition to implementation phase and overseas expansion from 2026 onward.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"StarlaPharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4888-20260810-01.pdf","jir_short_summary":"Reporting progress of R&D aimed at expanding BNCT indications into deep-seated cancer areas in collaboration with Fujita Medical University and others. Conducted exploratory research using 18F-FBPA PET, laying the groundwork for expanding indications to deep-seated tumors. Positioned as a pillar of the long-term growth strategy including transition to implementation phase and overseas expansion from 2026 onward.","jir_summary":"### Background and objectives of R&D\nStarlaPharma is pushing development targeting deep-seated cancers in collaboration with Fujita Medical University and other institutions to broaden BNCT treatments to more cancer types. BNCT combines boron agents with neutron irradiation, where tumor uptake and irradiation suitability are key to treatment success, making it essential to address technical challenges such as improving neutron reach for deeper regions.\n\n### Current projects and future outlook\nUnder the collaboration with Fujita Medical University, Atransen Pharma, Sumitomo Heavy Industries, and Fujita, started with a memorandum signed in December 2024 to advance BNCT research for deep-seated tumors. An deployment contract for BNCT treatment system and dose calculation program was signed in January 2026, moving toward concrete implementation. 18F-FBPA PET exploratory research will accumulate insights on boron agent behavior in deep-seated cancers to consider future indication expansion possibilities.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#StarlaPharma, #BNCTDevelopment","jir_key_figures":"R&D Memorandum Signed: December 2024\nBNCT treatment system deployment contract: January 2026\nNumber of target diseases: 50 cases (for 18F-FBPA PET exploratory research in deep-seated cancers)","jir_meta_title":"\u3010StarlaPharma\u3011BNCT deep-seated cancer indication expansion project progress with Fujita Medical University collaboration | August 2026","jir_meta_description":"StarlaPharma reports progress on research and development aimed at expanding BNCT indications in deep-seated cancers through collaboration with Fujita Medical University. Explains 18F-FBPA PET exploratory research and transition to deployment contracts and demonstration phase from 2026 onward.","jir_og_title":"\u3010StarlaPharma\u3011BNCT deep-seated cancer indication expansion project progress | August 2026","jir_og_description":"Introduces progress of R&D aiming to expand BNCT indications in deep-seated cancers through collaboration with Fujita Medical University. Focus on 18F-FBPA PET exploratory research and deployment contracts progress.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-99943","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n